AMENDMENTS TO THE CLAIMS

1. (previously presented) A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising

a. a therapeutically-effective amount of a pharmacologically active agent;

b. a crospovidone or povidone; and

c. a delivery agent for said pharmacologically active agent.

2. (previously presented) A composition according to claim 1 wherein the active agent is a peptide.

3. (previously presented) A composition according to claim 2 wherein the peptide is a calcitonin.

4. (previously presented) A composition according to claim 3 wherein the calcitonin is salmon calcitonin.

5. (previously presented) A composition according to claim 1 comprising crospovidone.

6. (previously presented) A composition according to claim 1 wherein the delivery agent is 5-CNAC.

7. (previously presented) A composition according to claim 1 wherein the delivery agent is the disodium salt of 5-CNAC.

8. (previously presented) A composition according to claim 1 which additionally includes a diluent.

9. (previously presented) A composition according to claim 8 wherein the diluent is microcrystalline cellulose.

10. (previously presented) A composition according to claim 1 which additionally includes a lubricant.

11. (previously presented) A composition according to claim 10 wherein the lubricant is magnesium stearate.

12. (withdrawn) A method for enhancing the oral bioavailability of a pharmacologically active agent, said method comprising administering to a patient in need of a pharmacologically active agent, an effective amount of a pharmaceutical composition according to claim1.

13. (withdrawn) A method of treatment of bone related diseases and calcium disorders comprising administering to a patient in need of such treatment a therapeutically effective amount of a composition according to claim 1, wherein said pharmacologically active agent is calcitonin.

14. (withdrawn) A method according to claim 13 wherein said calcitonin is salmon calcitonin.

15. (previously presented) A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising:

a. salmon calcitonin;
b. crospovidone;
c. 5-CNAC;
d. optionally, microcrystalline cellulose; and
e. optionally, magnesium stearate.

16. (currently amended) A solid pharmaceutical composition according to claim 15 wherein
a. the salmon calcitonin ~~comprises from~~ is present in an amount of from 0.05-70% by weight relative to the total weight of the overall pharmaceutical composition;
b. the crospovidone or povidone ~~comprises from~~ is present in an amount of from 0.5-50% by weight relative to the total weight of the overall pharmaceutical composition; and
c. the 5-CNAC is present in an amount of from 2.5-99.4% by weight relative to the total weight of the overall pharmaceutical composition.

17. (new) A solid pharmaceutical composition according to claim 15 wherein the crospovidone or povidone is present in an amount of from 2-25% by weight relative to the total weight of the overall pharmaceutical composition.

18. (new) A solid pharmaceutical composition according to claim 1 wherein
a. the pharmacologically active agent is present in an amount of from 0.05-70% by weight relative to the total weight of the overall pharmaceutical composition;
b. the crospovidone or povidone is present in an amount of from 0.5-50% by weight relative to the total weight of the overall pharmaceutical composition; and
c. the delivery agent for said pharmacologically active agent is present in an amount of 2.5-99.4% by weight relative to the total weight of the overall pharmaceutical composition.

19. (new) A solid pharmaceutical composition according to claim 18 wherein

the crospovidone or povidone is present in an amount of from 2-25% by weight relative to the total weight of the overall pharmaceutical composition.